Company
AADI -1.36%Aadi Bioscience, Inc.
Market Cap: $52.1 Million
USD as of May 5, 2024
$AADI -1.36% $AADI United States Healthcare Biotechnology US Healthcare US BiotechnologyTop Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $24.4 M |
| EBITDA | $-71,764,000 |
| Gross Profit TTM | $21.5 M |
| Profit Margin | -270.04% |
| Operating Margin | -280.02% |
| Quarterly Revenue Growth | 21.00% |